Cochlear Ltd
ASX:COH
Net Margin
Cochlear Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Cochlear Ltd
ASX:COH
|
16.4B AUD |
16%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
215.6B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.4B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
136.5B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
133.7B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.9B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.9B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
40.6B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
261.7B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
31.2B USD |
23%
|
Cochlear Ltd
Glance View
Cochlear Ltd., the renowned medical device company, traces its roots back to the vibrant medical innovation scene of Australia in the 1980s. Born from the pioneering research of Professor Graeme Clark, who was driven by a personal mission to help the hearing-impaired, Cochlear embarked on a journey that redefined the possibilities for those living with hearing loss. Over the years, the company has evolved into a global leader in implantable hearing solutions, headlined by its flagship cochlear implants. These intricate devices bypass damaged portions of the ear, directly stimulating the auditory nerve to restore the sense of hearing, thus providing users with the ability to connect more profoundly with the world around them. As scientific research advanced, so did Cochlear, developing a range of complementary products tailored to different degrees and types of hearing impairment. In a business model built on innovation and patient support, Cochlear generates revenue by designing, manufacturing, and marketing a portfolio of hearing implant products and related services. The company's value proposition lies not only in the initial sale of these high-tech devices but also in the ongoing customer relationships through upgrades, accessories, and maintenance services. By investing significantly in research and development, Cochlear ensures continuous improvement and the introduction of new solutions that meet the evolving needs of patients and healthcare providers. Their ability to offer comprehensive post-implantation support, such as rehabilitation services and patient care programs, strengthens customer loyalty and establishes recurring revenue streams, enabling Cochlear to maintain its competitive edge in the global market.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Cochlear Ltd's most recent financial statements, the company has Net Margin of 16.1%.
You don't have any saved screeners yet